Sign inJoin
Company / Finance

GE HealthCare Technologies Inc.

GEHC · NASDAQ

GE HealthCare reported 2025 revenue of $20.63 billion and Q1 2026 revenue of $5.13 billion. The thesis turns on whether imaging, ultrasound, patient-care and pharmaceutical-diagnostics scale can keep converting into margin and cash while debt, hospital capital budgets and China exposure remain visible risks.

FollowAdd to WatchlistAsk Question
NASDAQGEHCCoverage BootstrapGE HealthCare Technologies Inc.
Latest ReportMay 20, 2026GE HealthCare: the med-tech spinoff has to turn installed base into cashView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 company reports
Latest Thesis

GE HealthCare: the med-tech spinoff has to turn installed base into cash

GE HealthCare reported 2025 revenue of $20.63 billion and Q1 2026 revenue of $5.13 billion. The thesis turns on whether imaging, ultrasound, patient-care and pharmaceutical-diagnostics scale can keep converting into margin and cash while debt, hospital capital budgets and China exposure remain visible risks.

May 20, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
GE HealthCare Technologies Inc.HealthCare: the med-tech spinoff has to turn installed base intoMay 20, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
GE HealthCare: the med-tech spinoff has to turn installed base into cashGE HealthCare reported 2025 revenue of $20.63 billion and Q1 2026 revenue of $5.13 billion. The thesis turns on whether imaging, ultrasound, patient-care and pharmaceutical-diagnostics scale can keep converting into margin and cash while debt, hospital capital budgets and China exposure remain visible risks.NASDAQMay 20, 2026Research reportReadSlides